<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with a high prevalence of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and a high incidence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> lowering therapy with HMG Co-A reductase inhibitors (<z:chebi fb="0" ids="35664">statins</z:chebi>) reduce the risk of cardiovascular events in type 2 diabetic and non-diabetic patients, effects which are believed to be partly due to improvements in vascular function </plain></SENT>
<SENT sid="2" pm="."><plain>The aetiology of abnormal vascular function in type 2 diabetics is likely to be multifactorial and the pattern of vascular dysfunction in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> may differ from that which occurs in non-diabetic patients with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Abnormalities in endothelium derived hyperpolarising factor (EDHF) mediated vasodilation in resistance vessels may be more prominent in both type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> than in non-diabetic patients with <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering therapy on vascular responsiveness may differ in type 2 diabetic patients from those found in non-diabetic patients </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> therapy does not appear to improve responses to endothelial dependent <z:chebi fb="1" ids="35620">vasodilators</z:chebi> in type 2 diabetics, but may alter the ratio between nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) and EDHF mediated responses </plain></SENT>
<SENT sid="6" pm="."><plain>Fibrate therapy improves flow mediated dilation of brachial arteries in type 2 diabetic patients, but only appears to improve endothelium dependant <z:chebi fb="1" ids="35620">vasodilator</z:chebi> responses in resistance vessels when given in conjunction with co-enzyme Q </plain></SENT>
</text></document>